Cybin Announces Results of Annual and Special Meeting of Shareholders
- The acquisition of Small Pharma by Cybin was approved with 99.41% of votes in favor.
- Zeifmans LLP was appointed as the auditor of Cybin with 99.29% of votes in favor.
- The resolution to set the number of directors at six was approved with 98.71% of votes in favor.
- All nominees for election as directors were elected with high percentages of votes in favor.
- None.
1. Acquisition Resolution
The acquisition of Small Pharma Inc. (“Small Pharma”), by way of a proposed plan of arrangement under the Business Corporations Act (
Votes For |
Votes Against |
||
# |
% |
# |
% |
43,199,295 |
99.410 |
256,200 |
0.590 |
2. Appointment of Auditor
Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below:
Votes For |
Votes Withheld |
||
# |
% |
# |
% |
91,252,133 |
99.292 |
650,891 |
0.708 |
3. Number of Directors
The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
Votes For |
Votes Against |
||
# |
% |
# |
% |
90,712,567 |
98.705 |
1,190,458 |
1.295 |
4. Election of Directors
Each of the nominees for election as director listed in Cybin’s management information circular dated September 13, 2023 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below:
|
Votes For |
Votes Withheld |
||
|
# |
% |
# |
% |
Theresa Firestone |
42,976,922 |
98.899 |
478,573 |
1.101 |
Grant Froese |
43,022,128 |
99.003 |
433,368 |
0.997 |
Paul Glavine |
43,012,466 |
98.980 |
443,030 |
1.020 |
Eric Hoskins |
42,906,846 |
98.737 |
548,649 |
1.263 |
Mark Lawson |
42,971,117 |
98.885 |
484,379 |
1.115 |
Eric So |
39,668,729 |
91.286 |
3,786,767 |
8.714 |
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.
Headquartered in
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of COVID-19 on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2023, and the Company’s annual information form for the year ended March 31, 2023, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the
Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The
Neither Cboe Canada, operating as the Neo Exchange Inc., nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231012302314/en/
Investor & Media:
Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601
irteam@cybin.com – or – media@cybin.com
Source: Cybin Inc.
FAQ
What was the result of the acquisition resolution?
Who was appointed as the auditor of Cybin?
How many directors will Cybin have?